drugset / Trial / NCT04918589

Tranexamic Acid for Alloplastic Breast Reconstruction

NCT04918589

Phase 3 Unknown 106 enrolled McMaster University
RandomizedParallel-groupDouble-blindTreatment

Summary

Hematoma is a common complication of alloplastic breast reconstruction. This can lead to pain and discomfort experienced by the patient, in addition to greater use of valuable healthcare resources. Previous studies have shown correlation between the use of tranexamic acid (TXA), an anti-fibrinolytic, and reduced post-surgical bleeding complication events. In this randomized control trial (RCT) assessing TXA use in alloplastic breast reconstruction, one breast will be randomized to have TXA applied topically, while the other will have normal saline (NS) placebo applied. The primary objective of this prospective blinded randomized control trial study is to determine if the administration of topical TXA in alloplastic breast reconstruction reduces the incidence of surgical site hematoma compared to placebo within 2 weeks following surgery. The results of this study will be used to inform the design of a larger multicentered RCT on TXA in breast surgery.

Timeline

Start
2022-08
Primary completion
2024-08
Completion
2024-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 3 g

Indications